Physician profile
Pamela D Singleton
NPI 1396860037
$3,327.55
in general payments reported to CMS, 2019-2025
21 companies · $670 in 2025
The $670 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $581 · 2021: $331 · 2022: $303 · 2023: $220 · 2024: $251 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.73 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $886.11 | 2019-2024 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $498.74 | 2019-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Abbvie INC. | $444.51 | 2020-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $413.95 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $259.07 | 2019-2021 | |
| Avion Pharmaceuticals | $233.70 | 2019-2021 | |
| Dexcom, INC. | $160.78 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Mayne Pharma Commercial LLC | $102.62 | 2022 | |
| Therapeuticsmd, INC. | $77.16 | 2019 | |
| Roche Diagnostics Corporation | $27.92 | 2019 | |
| Biogen, INC. | $26.20 | 2025 | Zurzuvae |
| Organon LLC | $25.91 | 2024 | |
| Exeltis, USA INC. | $24.66 | 2020 | |
| Medtronic, INC. | $24.42 | 2023 | Truclear |
| Agile Therapeutics, INC. | $22.35 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2019 | |
| Minerva Surgical, INC | $19.75 | 2024 | |
| Coopersurgical, INC. | $16.14 | 2024 | Paragard T 380a |
| Pfizer INC. | $15.78 | 2024 | |
| Allergan, INC. | $15.33 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.